Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Mitosol®'s Orphan Drug Designation is Expanded for All Glaucoma Surgery

Mobius Therapeutics,LLC
Posted on: 31 Oct 17
Mitosol®'s Orphan Drug Designation is Expanded for All Glaucoma Surgery St. Louis ophthalmic company expands designation to include all glaucoma surgery

PR Newswire

ST. LOUIS, Oct. 31, 2017

ST. LOUIS, Oct. 31, 2017 /PRNewswire/ -- Mobius Therapeutics™, LLC, a St. Louis-based ophthalmic company, has expanded its Orphan Drug Designation from the Food and Drug Administration for its platform product, Mitosol®, to now read "Treatment of refractory glaucoma as an adjunct to surgery."

By expanding this orphan drug indication, Mobius Therapeutics™ may now assume the benefits of orphan drug designation for new and evolving MIGS procedures used in the treatment of glaucoma. 

"This expanded designation offers the benefits of Mitosol® in new and evolving procedures employing an ab interno approach, versus traditional ab externo approaches," said Ed Timm, president of Mobius Therapeutics™.  "New MIGS procedures, typified by the XEN® Gel Stent, have relied upon Mitosol® as a companion drug during pivotal clinical trials. Going forward, we may now pursue these indications, assuring these patients and providers that the precision, safety and unprecedented convenience of Mitosol® will be available to all."

About Mobius Therapeutics, LLC:

Mobius Therapeutics™ is a commercial stage venture focused upon perioperative sterile injectables used in ophthalmic surgery. Its first product, Mitosol®, is the only FDA approved formulation of mitomycin-c bearing an ophthalmic indication. Mobius maintains an active sterile injectable product pipeline in varying stages of development. Please see full prescribing information at and

XEN® is a registered trademark of Allergan, Inc.

Related Images

Mitosol (mitomycin for solution) Kit for Ophthalmic Use

Mobius Therapeutics

Related Links

Mitosol Prescribing Information

Amphadase Prescribing Information

View original content with multimedia:

SOURCE Mobius Therapeutics, LLC

PR Newswire

Last updated on: 31/10/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.